Certara Announces Pricing of Public Offering of Common Stock

PRINCETON, N.J., November 17, 2021. — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the pricing of its underwritten public offering of 10 million shares of its common stock by certain existing stockholders (the “selling stockholders”) at a price to the public of $31.00 per share. Additionally, the selling stockholders have granted the underwriters … Continued

Certara Announces Proposed Public Offering of Common Stock

PRINCETON, N.J.– November 15, 2021– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced a proposed underwritten public offering by certain selling stockholders of 10 million shares of its common stock pursuant to a registration statement filed with the Securities and Exchange Commission. Additionally, the selling stockholders intend to grant the underwriters a … Continued

Certara Appoints Patrick F. Smith to President of Integrated Drug Development

Princeton, N.J., October 12, 2021 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Patrick F. Smith, Pharm.D. as president of Integrated Drug Development (IDD), reporting to CEO William F. Feehery.  Dr. Smith will lead the Company’s global drug development services team, which creates value for clients across the … Continued

Certara Announces Proposed Public Offering of Common Stock

PRINCETON, N.J.—September 3, 2021. Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced a proposed underwritten public offering of 20,000,000 shares of its common stock pursuant to a registration statement filed with the Securities and Exchange Commission. Certara is offering 4,500,000 shares of common stock and certain selling stockholders are offering 15,500,000 shares … Continued

Mubadala Invests in Global Biosimulation Leader Certara

Princeton, N.J., July 27, 2021: Certara (NASDAQ: CERT), a global leader in biosimulation, today announced that Mubadala Investment Company (Mubadala) has made an approximately $250 million investment in Certara.  The investment aligns with Mubadala’s strategy of enabling innovation to address unmet clinical needs and drive cost efficiencies. Mubadala and certain existing institutional shareholders of Certara, including … Continued

Certara Appoints Dr. Carol Gallagher as New Independent Board Member

Dr. Gallagher brings more than 30 years of drug development and commercial leadership experience to her new role PRINCETON, N.J.—June 14, 2021.  Certara, a global leader in biosimulation, today announced the addition of Carol Gallagher, Pharm.D., to its board of directors.  Dr. Gallagher is an experienced biopharmaceutical director and operator and serves as a venture … Continued

Certara Acquires UK-based Insight Medical Writing

Expands global reach and deepens regulatory expertise PRINCETON, NJ.— June 10, 2021– Certara, Inc., the global leader in biosimulation, today announced the acquisition of Insight Medical Writing, based in Oxford in the United Kingdom.  Financial terms of the transaction were not disclosed. Founded in 2002, Insight Medical Writing offers regulatory services and medical writing. Its … Continued

1 of 9
Back to top
Powered by Translations.com GlobalLink OneLink Software